NLK, a novel target of miR-199a-3p, functions as a tumor suppressor in colorectal cancer

Biomedicine and Pharmacotherapy

Volumn 68, Issue 5, 2014, Pages 497-505

  Han, Ye ^a   Kuang, Yuting ^a   Xue, Xiaofeng ^a   Guo, Xiaobo ^b   Li, Pu ^c   Wang, Xu ^a   Guo, Xingpo ^a   Yuan, Bin ^a   Zhi, Qiaoming ^a   Zhao, Hong ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Colorectal cancer; MiR 199a 3p; NLK; Tumor suppressor

Indexed keywords

MICRORNA; MICRORNA 199A 3P; NEMO LIKE KINASE; PROTEIN SERINE THREONINE KINASE; UNCLASSIFIED DRUG; 3' UNTRANSLATED REGION; MIRN199 MICRORNA, HUMAN; NLK PROTEIN, HUMAN; SIGNAL PEPTIDE; SMALL INTERFERING RNA;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CELL MIGRATION; CELL PROLIFERATION; CLONOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE OVEREXPRESSION; HCT116 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; KAPLAN MEIER METHOD; LIVER METASTASIS; LUCIFERASE ASSAY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; WOUND HEALING; 3' UNTRANSLATED REGION; BINDING SITE; CELL MOTION; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; STAINING; SURVIVAL RATE; TUMOR CELL LINE; TUMOR STEM CELL ASSAY; UPREGULATION;

3' UNTRANSLATED REGIONS; APOPTOSIS; BASE SEQUENCE; BINDING SITES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HEK293 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICRORNAS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM INVASIVENESS; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; STAINING AND LABELING; SURVIVAL RATE; TUMOR STEM CELL ASSAY; UP-REGULATION; WOUND HEALING;

EID: 84905095554     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2014.05.003     Document Type: Article

References (29)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Funaioli C., Longobardi C., Martoni A.A. The impact of chemotherapy on overall survival and quality of life of patients with metastatic colorectal cancer: a review of phase III trials. J Chemother 2008, 20:14-27.
3. Anwar S., Frayling I.M., Scott N.A., Carlson G.L. Systematic review of genetic influences on the prognosis of colorectal cancer. Br J Surg 2004, 91:1275-1291.
4. Cai Y., Yu X., Hu S., Yu J. A brief review on the mechanisms of miRNA regulation. Genomics Proteomics Bioinformatics 2009, 7:147-154.
5. Di Leva G., Croce C.M. miRNA profiling of cancer. Curr Opin Genet Dev 2013, 23:3-11.
6. Dahiya N., Sherman-Baust C.A., Wang T.L., Davidson B., Shih Ie M., Zhang Y., et al. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PloS One 2008, 3:e2436.
7. Ruvkun G. Clarifications on miRNA and cancer. Science 2006, 311:36-37.
8. Pichler M., Winter E., Stotz M., Eberhard K., Samonigg H., Lax S., et al. Down-regulation of KRAS-interacting miRNA-143 predicts poor prognosis but not response to EGFR-targeted agents in colorectal cancer. Br J Cancer 2012, 106:1826-1832.
9. Schee K., Boye K., Abrahamsen T.W., Fodstad O., Flatmark K. Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer. BMC Cancer 2012, 12:505.
10. Wan D., He S., Xie B., Xu G., Gu W., Shen C., et al. Aberrant expression of miR-199a-3p and its clinical significance in colorectal cancers. Med Oncol 2013, 30:378.
11. Ishitani T., Hirao T., Suzuki M., Isoda M., Ishitani S., Harigaya K., et al. Nemo-like kinase suppresses Notch signalling by interfering with formation of the Notch active transcriptional complex. Nat Cell Biol 2010, 12:278-285.
12. Ishitani T., Ishitani S., Matsumoto K., Itoh M. Nemo-like kinase is involved in NGF-induced neurite outgrowth via phosphorylating MAP1B and paxillin. J Neurochem 2009, 111:1104-1118.
13. Harada H., Yoshida S., Nobe Y., Ezura Y., Atake T., Koguchi T., et al. Genomic structure of the human NLK (nemo-like kinase) gene and analysis of its promoter region. Gene 2002, 285:175-182.
14. Li M., Zhang S., Wang Z., Zhang B., Wu X., Weng H., et al. Prognostic significance of nemo-like kinase (NLK) expression in patients with gallbladder cancer. Tumour Biol 2013, 34:3995-4000.
15. Zhang B., Li K.Y., Chen H.Y., Pan S.D., Chen S.F., Zhang W.F., et al. Lentivirus-based RNA silencing of Nemo-like kinase (NLK) inhibits the CAL 27 human adenosquamos carcinoma cells proliferation and blocks G0/G1 phase to S phase. Int J Med Sci 2013, 10:1301-1306.
16. Lv L., Wan C., Chen B., Li M., Liu Y., Ni T., et al. Nemo-like kinase (NLK) inhibits the progression of NSCLC via negatively modulating WNT signaling pathway. J Cell Biochem 2014, 115:81-92.
17. Jung K.H., Kim J.K., Noh J.H., Eun J.W., Bae H.J., Xie H.J., et al. Targeted disruption of Nemo-like kinase inhibits tumor cell growth by simultaneous suppression of cyclin D1 and CDK2 in human hepatocellular carcinoma. J Cell Biochem 2010, 110:687-696.
18. Emami K.H., Brown L.G., Pitts T.E., Sun X., Vessella R.L., Corey E. Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells. Prostate 2009, 69:1481-1492.
19. Salim H., Akbar N.S., Zong D., Vaculova A.H., Lewensohn R., Moshfegh A., et al. miRNA-214 modulates radiotherapy response of non-small cell lung cancer cells through regulation of p38MAPK, apoptosis and senescence. Br J Cancer 2012, 107:1361-1373.
20. Zhao R., Zhou M., Wang H., Xiong W., Li X., Li G. [MiRNA regulatory mechanism in tumor initiation and progression]. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2013, 38:1282-1288.
21. Song G., Zeng H., Li J., Xiao L., He Y., Tang Y., et al. miR-199a regulates the tumor suppressor mitogen-activated protein kinase kinase kinase 11 in gastric cancer. Biol Pharmaceut Bull 2010, 33:1822-1827.
22. Henry J.C., Park J.K., Jiang J., Kim J.H., Nagorney D.M., Roberts L.R., et al. miR-199a-3p targets CD44 and reduces proliferation of CD44 positive hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 2010, 403:120-125.
23. Fornari F., Milazzo M., Chieco P., Negrini M., Calin G.A., Grazi G.L., et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2010, 70:5184-5193.
24. Duan Z., Choy E., Harmon D., Liu X., Susa M., Mankin H., et al. MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration. Mol Cancer Ther 2011, 10:1337-1345.
25. Wu D., Huang H.J., He C.N., Wang K.Y. MicroRNA-199a-3p regulates endometrial cancer cell proliferation by targeting mammalian target of rapamycin (mTOR). Int J Gynecol Cancer 2013, 23:1191-1197.
26. Huang Y., Jiang Y., Lu W., Zhang Y. Nemo-like kinase associated with proliferation and apoptosis by c-Myb degradation in breast cancer. PloS One 2013, 8:e69148.
27. Zhang Y., Peng C., Wu G., Wang Y., Liu R., Yang S., et al. Expression of NLK and its potential effect in ovarian cancer chemotherapy. Int J Gynecol Cancer 2011, 21:1380-1387.
28. Cui G., Li Z., Shao B., Zhao L., Zhou Y., Lu T., et al. Clinical and biological significance of nemo-like kinase expression in glioma. J Clin Neurosci 2011, 18:271-275.
29. Dong J.R., Guo N., Zhao J.P., Liu P.D., Feng H.H., Li Y. Inhibition of nemo-like kinase increases taxol sensitivity in laryngeal cancer. APJCP. 2013, 14:7137-7141.